Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    AOD-9604

    Metabolic & Weight Loss

    Status
    Phase 2, , not approved for human use
    Evidence

    Failed human trial, sponsor-reported, graded on the Fat Loss Peptides Bench

    AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe).

    Reviewed

    01Overview

    What AOD-9604 is

    It was developed in the 1990s-2000s by Professor Frank Ng and colleagues at the Howard Florey Institute (University of Melbourne) and commercialized by Metabolic Pharmaceuticals Australia with the specific goal of isolating the "lipolytic" (fat-burning) domain of growth hormone while separating it from the "growth-promoting" domain that drives IGF-1-mediated effects, glucose intolerance, and soft-tissue growth. The underlying scientific rationale came from a series of studies in the 1980s-1990s showing that specific C-terminal fragments of hGH retained the fat-metabolism-improving effects of full-length hGH in rodent models without causing IGF-1 elevation, glucose intolerance, or cartilage/organ growth ([Ng et al., 2000]).

    Read the full overviewShow less

    Despite this attractive preclinical profile, AOD-9604's clinical trial history has been disappointing. The key Phase 2B trial gave obese adults oral AOD-9604 tablets (0.25, 0.5 or 1 mg daily) or placebo for 24 weeks (534 enrolled, 502 randomized); it did not meet its primary weight-loss endpoint ([Dominikowski et al., 2026]). The sponsor reported this in 2007, not in a peer-reviewed paper; safety data from this and five other randomized trials appear in [Stier et al., 2013]. The trial was a commercial and clinical failure, leading Metabolic Pharmaceuticals to abandon obesity development and ultimately exit the pharmaceutical business entirely. AOD-9604 was never approved as a drug in any country for any indication.

    However, AOD-9604 has enjoyed a peculiar second life in two contexts: (1) as a marketed ingredient in oral supplements claiming "fat burning" properties in the US following FDA's 2014 GRAS (Generally Recognized as Safe) determination for use as a food ingredient at low doses — a determination that did not assess efficacy, only safety; and (2) as a widely-marketed research peptide sold by "research chemical" suppliers for injectable use at peptide-tuning doses (250-500 mcg daily), typically combined in stacks with other compounds for body composition tuning. Notably, the GRAS designation for oral consumption is scientifically odd given that AOD-9604 is a peptide that would be expected to be degraded by gastric acid and digestive proteases with minimal systemic bioavailability — effectively meaning oral AOD-9604 supplements likely deliver negligible active peptide to the circulation.

    Cross-references include Tesamorelin (FDA-approved GHRH analog for visceral fat with genuine clinical evidence), Ipamorelin (GH secretagogue with pulsatile release), CJC-1295 (long-acting GHRH analog), Sermorelin (GHRH analog), MOTS-c (mitochondrial metabolic peptide), and 5-Amino-1MQ (NNMT inhibitor for fat loss).

    How it works

    AOD-9604's claimed mechanism is lipolysis (fat breakdown) via a C-terminal hGH-fragment-specific pathway distinct from classical growth hormone receptor signaling, though the mechanistic details remain incompletely characterized and contested.

    Read the full mechanismShow less

    The "Lipolytic Fragment" Hypothesis: In the 1990s, Frank Ng and colleagues at the Howard Florey Institute proposed that full-length hGH contains functionally distinct domains - an N-terminal domain responsible for growth-promoting effects (IGF-1 elevation, cartilage/organ growth) and a C-terminal domain (residues 177-191) responsible for lipolytic and anti-lipogenic effects. AOD-9604 was engineered as a synthetic version of this proposed lipolytic domain, with an added N-terminal tyrosine for stability and receptor binding.

    Proposed Mechanisms:

    • Beta-3 adrenergic receptor (3-AR) modulation: preclinical studies in obese mice suggested AOD-9604 increases 3-AR expression in adipose tissue (Heffernan et al., 2001; PubMed 11713213); notably, that same study concluded the lipolytic action is NOT mediated directly through 3-AR, even though 3-AR expression rose. 3-AR is enriched in white and brown adipose tissue in rodents and mediates fat oxidation; however, 3-AR expression in human adipose is much lower than in rodents, potentially explaining the translation failure.
    • Inhibition of lipogenesis: suggested to reduce de novo fatty acid synthesis in adipocytes.
    • Mobilization of stored fat: claimed to shift metabolism toward fat oxidation.
    • No IGF-1 elevation: critically, AOD-9604 does not activate the growth hormone receptor in a manner that triggers hepatic IGF-1 production - it does not compete for the hGH receptor and does not induce cell proliferation in vitro (Heffernan et al., 2001; PubMed 11673763). This is the primary differentiating feature from full-length hGH or secretagogues like Ipamorelin or CJC-1295.

    Pharmacokinetic Profile:

    • Molecular weight: ~1815 Da (16-amino-acid peptide, disulfide-bonded form)
    • Half-life: ~30-60 minutes for injectable administration (short)
    • Subcutaneous absorption: adequate
    • Oral bioavailability: negligible to very low in humans - peptides of this size are typically degraded in gastric acid and by intestinal proteases with minimal systemic absorption; oral supplement claims are mechanistically implausible unless a specialized formulation achieves unusual stability (not demonstrated for commercial products)

    What the Human Trials Revealed: The developer's human obesity program (Phase 2) did not confirm the rodent efficacy signal: the larger/longer studies did not produce statistically significant weight loss versus placebo, and obesity development was discontinued (~2007). Importantly, these human efficacy results were reported by the sponsor and in secondary/review sources but were NOT published as a peer-reviewed, PubMed-indexed randomized controlled trial - so there is no primary published human efficacy paper to cite, positive or negative. The failure to translate suggests one or more of: (1) the proposed 3-AR-linked mechanism does not carry over from rodents to humans (human adipose expresses far less 3-AR than rodent), (2) the doses or duration tested were insufficient, or (3) the preclinical rodent findings reflected species-specific physiology. Without peer-reviewed positive human efficacy data, AOD-9604 cannot be considered a scientifically validated fat-loss intervention.

    Why the Marketing Persists: Despite the lack of human efficacy data, AOD-9604 continues to be heavily marketed in three channels:

    1. Oral supplements in the US: a 2014 self-affirmed GRAS determination for low-dose oral use in foods/supplements is technically a food-safety determination, not a drug-efficacy determination. Marketers use GRAS status to imply FDA endorsement while the actual science does not support oral efficacy.
    2. "Research peptides" for injectable use: sold online as research chemicals, with explicit disclaimers that they are "not for human consumption" but with marketing materials targeting fitness enthusiasts and body-composition optimizers.
    3. Stack combinations: often bundled with Ipamorelin, CJC-1295, MOTS-c, or other peptides as "fat-loss stacks" where the true efficacy driver is typically the other component.

    Comparison to Validated Alternatives:

    • Tesamorelin: FDA-approved GHRH analog with rigorous Phase 3 evidence for visceral fat reduction in HIV-associated lipodystrophy - the only GH-axis peptide with proven human efficacy for fat loss.
    • Semaglutide, Tirzepatide, Orforglipron: GLP-1 class drugs with overwhelming Phase 3 evidence for weight loss of 15-22%.
    • Ipamorelin + CJC-1295: raise endogenous GH and IGF-1, with mechanism-plausible body composition effects (though limited Phase 3 data specifically for fat loss as primary endpoint).

    If the goal is fat loss or body composition tuning, AOD-9604 should not be a first-line choice given the absence of positive human evidence. Patients considering AOD-9604 should understand they are using a compound whose human obesity program was discontinued for lack of efficacy, that is not FDA-approved as a drug, and that has no published peer-reviewed evidence of efficacy in humans.

    Studied for

    • Obesity
    • Osteoarthritis
    • Metabolic syndrome
    • Body composition

    Benefits listed

    • Claimed lipolysis / fat loss (demonstrated only in rodent studies; not shown in human trials)
    • Does not raise IGF-1 or activate the GH receptor (no growth or proliferative signaling)
    • Does not impair insulin sensitivity or glucose tolerance in studies to date
    • Benign short-term safety and tolerability profile
    Show 1 moreShow less
    • Cartilage-protective effect in an animal (rabbit) osteoarthritis model - preclinical only

    02Research

    Free with email

    What the research shows

    Graded on a research bench

    Reference pages that put AOD-9604 next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    AOD-9604 side effects and interactions

    Side effects

    Low risk

    Stop use if

    • Active malignancy
    • Known peptide hormone hypersensitivity

    Common

    • Mild injection site reactions
    • Headache
    • Nausea (rare)

    Less common

    • Transient blood pressure changes

    Who should not use it

    Contraindications

    Absolute Contraindications:

    • Prior serious hypersensitivity to AOD-9604 or peptide excipients
    • Pregnancy: contraindicated due to inadequate safety data in pregnancy
    • Active lactation: contraindicated due to inadequate safety data for breastfeeding infants
    • Pediatric patients under 18: no safety or efficacy data; avoid
    Read all the contraindications and cautionsShow less

    Relative Contraindications / Use With Extreme Caution:

    • Active malignancy: theoretical concern with any peptide therapy; though AOD-9604 doesn't activate the GH receptor for growth, caution advised until evidence establishes safety in cancer populations
    • Active critical illness: in ICU populations, growth hormone therapy has paradoxical increased mortality in some studies; AOD-9604's different mechanism may not share this concern, but caution is warranted
    • Severe immunodeficiency: theoretical injection-site infection risk may be elevated
    • Active eating disorder (particularly anorexia nervosa or body dysmorphic disorder): marketing AOD-9604 as a fat-loss tool to someone with these conditions risks worsening disordered eating patterns
    • Severe psychological vulnerability to body image issues: careful screening before prescribing or providing peptide access

    Situations Where AOD-9604 Is Inappropriate:

    As a substitute for evidence-based obesity treatment:

    • Patient with clinically significant obesity (BMI >=30 or >=27 with comorbidities) whose primary need is effective weight loss
    • Patients with prior failure of lifestyle interventions who need pharmacotherapy: choose GLP-1 class drugs over AOD-9604
    • Patients with comorbidities that would benefit from effective weight loss: diabetic retinopathy, sleep apnea, osteoarthritis, NASH, cardiovascular disease

    As a substitute for structured nutrition and exercise:

    • AOD-9604 is not a replacement for caloric deficit and physical activity
    • Patients should not delay or substitute lifestyle interventions for peptide therapy

    Practitioner / Clinical Considerations:

    Regulatory status in your jurisdiction:

    • Research peptide form: illegal to sell for human use in most jurisdictions; personal possession typically unenforced but legally ambiguous
    • Oral supplement form: marketed in the US under a self-affirmed GRAS determination; status varies by country
    • Compounded pharmacy form: may be available with prescription in specific situations

    Liability exposure:

    • Prescribing or recommending non-FDA-approved peptides carries professional liability
    • Document informed consent thoroughly if involved in patient care decisions
    • Educate patients about evidence-based alternatives before AOD-9604

    Situations Requiring Discontinuation:

    Develop during use:

    • New or worsening injection site complications
    • Any systemic allergic reaction
    • Development of pregnancy
    • Development of diagnosable malignancy
    • Clinical indication for effective weight loss therapy (switch to evidence-based treatment)

    Intermittent evaluation:

    • No objective benefit at 12 weeks: discontinue
    • Cost-benefit no longer favorable: discontinue
    • Access to evidence-based alternative becomes available: transition
    • Achievement of goal through other means: discontinue as unnecessary

    Drug Interactions:

    No clinically significant drug interactions documented. AOD-9604 does not:

    • Interact with cytochrome P450 enzymes
    • Significantly alter absorption of other medications
    • Compete with other peptide therapies at known receptors
    • Potentiate or inhibit common prescription drugs

    Theoretical considerations:

    • With other injected peptides: additive injection volume and site rotation needs
    • With anticoagulants: injection site bruising may be more pronounced
    • With immunosuppressants: injection site infection risk may be slightly elevated

    Athletic / Sport-Specific Considerations:

    WADA (World Anti-Doping Agency) status:

    • AOD-9604 is PROHIBITED in sport at all times under WADA Prohibited List class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It has been specifically identified as a WADA-banned peptide, and validated urine detection methods for AOD-9604 and its stable metabolite have been published (PubMed 25208511).
    • Any competitive athlete subject to WADA rules should not use it; the substance is directly covered, and use can result in an anti-doping rule violation.
    • Detection windows are extended by screening for the stable serum/urine metabolite (CRSVEGSCG).

    Non-WADA testing (NCAA, professional leagues):

    • Varies by organization; many follow WADA classifications
    • Broad peptide panels can detect AOD-9604 or its metabolites

    Safety Communication With Patients:

    Key points to convey:

    • AOD-9604's human obesity program did not confirm efficacy and was discontinued
    • There is no published peer-reviewed human trial showing weight-loss benefit
    • The GRAS status is about food safety, not drug efficacy
    • Injectable forms are not FDA-approved and are sold as "research chemicals"
    • Quality of research peptides varies
    • It is prohibited in sport by WADA
    • Evidence-based alternatives exist for weight loss
    • AOD-9604 is unlikely to cause significant harm but is also unlikely to produce significant weight loss
    • Decision to use is ultimately about patient autonomy in a context of limited expected benefit
    • Cost of AOD-9604 may be better allocated elsewhere

    Emergency Considerations:

    • In case of severe allergic reaction: epinephrine, antihistamines, supportive care
    • Injection site infection: standard wound care, antibiotics if indicated
    • Accidental intravascular injection: minimal clinical significance expected with this peptide; monitor
    • Overdose: no specific toxicity syndrome; supportive care

    Interactions

    4 pairings in our record: 1 with a caution and 3 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • HGH Fragment 176-191

      Caution

      Both are HGH fragment derivatives — similar mechanisms, do not stack

    • BPC-157

      Compatible

      Different healing mechanisms — AOD for fat loss, BPC for tissue repair

    • Semaglutide

      Compatible

      Complementary fat loss mechanisms — appetite suppression + lipolysis

    • L-Carnitine

      Synergistic

      Both support fat metabolism

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    AOD-9604 dosage and protocols

    Dose range
    250–600 mcg per injection
    Dosing
    Once daily, typically morning fasted
    Common vials
    2mg, 5mg

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Dose, route, how often and how long
    • A titration schedule
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    AOD-9604 prices

    5 listings from 4 vendors, opening in the Featured order.

    Pack prices
    $34.99 to $59.99
    Lowest per mg
    $7.00/mg
    Vendors
    4
    Listings
    5 (vial)

    Prices as the vendors list them, last recorded 8 October 2026.

    Form
    Sort
    AOD-9604 listings, in Featured order
    VendorProductPriceBuy

    AOD-9604

    vial, 1 vial

    In stock

    $59.99

    No mg count

    Buy AOD-9604 at Disguised Alpha

    AOD-9604 5mg

    vial, 1 vial

    Out of stock

    $9.80/mg

    $49.00

    View AOD-9604 5mg at Ion Peptide

    AOD-9604 5mg

    vial, 1 vial

    In stock

    $7.00/mg

    $34.99

    Lowest per mg
    Buy AOD-9604 5mg at BioMyst Labs

    AOD-9604 5mg

    vial, 1 vial

    In stock

    $7.00/mg

    $34.99

    Lowest per mg
    Buy AOD-9604 5mg at BioMyst Labs

    AOD-9604 5mg

    vial, 5mg vial

    In stock

    $7.00/mg

    $34.99

    Lowest per mg
    Buy AOD-9604 5mg at Half Nattys
    Vendors selling AOD-9604(4: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Price history(4 days with a recorded price)
    Review AOD-9604

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with AOD-9604.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C78H123N23O23S2
    Molecular mass
    1815.1 g/mol
    CAS number
    221231-10-3
    IUPAC name
    Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
    Amino acid sequence
    Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (single-letter: YLRIVQCRSVEGSCGF). A 16-residue synthetic analog of the C-terminal fragment of human growth hormone (hGH residues 177-191) with an N-terminal tyrosine added; contains an intramolecular disulfide bond between Cys7 and Cys14 (corresponding to hGH Cys182-Cys189). Identity confirmed by anti-doping mass-spectrometry characterization (PubMed 25208511), which also identified the stable serum metabolite CRSVEGSCG.
    View on PubChem

    08Questions

    Frequently asked questions

    Does AOD-9604 actually work for fat loss?

    The honest answer is no - there is no published human evidence that AOD-9604 produces meaningful weight loss. Its rodent data (reduced fat gain and increased lipolysis in obese rats and mice; PubMed 11146367, 11673763) did not translate: the developer's human obesity program did not demonstrate significant weight loss versus placebo and was discontinued (~2007), and those results were never published as a peer-reviewed randomized controlled trial. (An earlier version of this page cited a 'Heffernan 2008' 536-patient trial; no such paper exists. The real 24-week trial gave oral tablets to 502 randomized adults, and the sponsor reported in 2007 that it missed its weight-loss endpoint.) Anecdotal reports of fat loss in peptide communities are not supported by controlled evidence and are likely attributable to concurrent lifestyle changes, placebo effects, or regression to the mean. For evidence-based weight loss, GLP-1 agonists like Semaglutide, Tirzepatide, or Orforglipron have overwhelming Phase 3 evidence.

    If AOD-9604 failed to show efficacy, why is it still sold?

    Three main reasons: (1) In 2014, a self-affirmed GRAS (Generally Recognized as Safe) determination was made for oral use in foods and dietary supplements at low doses. This is a food-safety determination, not an efficacy determination, but marketers leverage GRAS status to imply FDA endorsement. (2) 'Research peptide' suppliers sell injectable AOD-9604 with 'not for human consumption' disclaimers, creating a legal gray area while explicitly targeting body-composition optimizers. (3) The original preclinical rodent data showed fat-loss effects, and this narrative continues to be used in marketing materials despite the human failure. The oral form is mechanistically unlikely to produce effects (peptide degraded by gastric acid before absorption), and the injectable form has no positive controlled human trial data.

    What's the difference between AOD-9604 and growth hormone?

    AOD-9604 is a 16-amino-acid fragment of hGH (residues 177-191 with an added tyrosine), while full-length hGH is a 191-amino-acid protein. The design rationale was that C-terminal fragments retain the fat-metabolism effects of hGH without the growth-promoting effects (IGF-1 elevation, cartilage/organ growth, glucose intolerance). AOD-9604 does not activate the growth hormone receptor in a way that triggers IGF-1 production - this was confirmed in studies showing it does not bind the hGH receptor or induce cell proliferation (PubMed 11673763) - and is the primary distinguishing feature. The tradeoff: AOD-9604 also lacks the fat-loss efficacy that hGH demonstrates in humans. Full-length hGH produces significant fat loss in hGH-deficient adults but at the cost of side effects; AOD-9604 has fewer side effects but also no demonstrated human efficacy. Tesamorelin, by contrast, is a GHRH analog that stimulates pulsatile endogenous GH release - it has FDA approval for HIV-related visceral fat reduction and is a more evidence-based choice for GH-axis-mediated fat loss.

    Can AOD-9604 be taken orally as a supplement?

    AOD-9604 is marketed in oral supplement form following the 2014 GRAS determination. However, as a 16-amino-acid peptide, oral bioavailability is expected to be essentially zero - peptide bonds are cleaved by gastric acid and pancreatic proteases (trypsin, chymotrypsin, etc.) before the peptide can be absorbed. Unless a specialized formulation (enteric coating, absorption enhancers like SNAC, liposomal encapsulation) is used to protect the peptide through the GI tract, oral AOD-9604 likely delivers negligible active peptide to the circulation. Most commercial oral AOD-9604 products do not use such advanced formulation technologies. Oral AOD-9604 should be considered likely ineffective for any systemic physiological effect; any perceived benefit is probably placebo or attributable to other ingredients in the supplement.

    Is AOD-9604 safer than other weight loss drugs?

    AOD-9604 does have a notably benign side effect profile - in the developer's human trials it caused minimal adverse events, no IGF-1 elevation, no glucose intolerance, and no significant issues across the doses studied. This is sometimes framed as a 'safety advantage' over other weight loss agents. However, this framing misses a critical point: the reason for AOD-9604's benign profile is that it does very little physiologically - a drug that doesn't work also doesn't cause side effects. Compared to GLP-1 agonists (nausea, GI effects, rare pancreatitis), AOD-9604 is less likely to cause any unpleasant symptoms. But GLP-1 agonists produce 15-22% weight loss, whereas AOD-9604 has no demonstrated weight-loss benefit beyond placebo in humans. The real question isn't 'which is safer' but 'which provides a favorable benefit-to-risk ratio.' For clinically significant weight loss, GLP-1 agonists provide substantial benefit at manageable risk; AOD-9604 provides negligible benefit at minimal risk but at meaningful cost and the opportunity cost of not pursuing evidence-based treatment.

    How do I know if my AOD-9604 is real?

    Research peptide quality varies substantially. Indicators of a legitimate product: (1) Clean, professional packaging with batch/lot numbers and expiration dates; (2) Vendor provides a certificate of analysis (COA) showing peptide identity (mass spectrometry), purity (HPLC >=95%), and endotoxin testing (<1 EU/mg); (3) Appearance after reconstitution is clear, colorless, free of particulates; (4) Consistent experience across multiple orders from the same vendor. Red flags: vendor won't provide a COA, product appears cloudy or discolored, significantly varying effects between vials, unusually low pricing (legitimate research peptides have a production cost floor). For absolute verification, independent third-party testing is possible through specialized labs but rarely done by individual users. Many peptide users accept some quality uncertainty as part of using research-grade products outside pharmaceutical channels. This is another argument against AOD-9604 specifically - given uncertain efficacy AND uncertain product quality, the cumulative probability of a therapeutic effect is low.

    Can I combine AOD-9604 with GLP-1 agonists like semaglutide?

    Yes, there are no known drug interactions between AOD-9604 and GLP-1 agonists, and the mechanisms are non-overlapping. However, in practical terms, if you are taking a GLP-1 agonist with 15-20% weight loss efficacy, the incremental benefit of adding AOD-9604 is negligible - essentially all the weight loss will be from the GLP-1 agonist, and AOD-9604 adds cost and injection burden without proven benefit. Most experienced practitioners would recommend GLP-1 monotherapy at optimal doses rather than combination with AOD-9604. If you're looking for GLP-1 adjuncts with better mechanistic rationale, consider: Cagrilintide (amylin analog with Phase 3 evidence in CagriSema trials), Tesamorelin (FDA-approved GHRH analog for visceral fat), or optimized resistance training for body composition.

    Does AOD-9604 help with joint pain or cartilage repair?

    Metabolic Pharmaceuticals attempted to reposition AOD-9604 for osteoarthritis after the obesity program stalled, citing preclinical chondroprotective data. The main supportive evidence is preclinical: intra-articular AOD9604 (alone or with hyaluronic acid) improved cartilage regeneration in a collagenase-induced rabbit osteoarthritis model (PubMed 26275694). Published human clinical trial evidence for AOD-9604 in osteoarthritis or cartilage repair is lacking and does not support the strong claims made in marketing materials for joint applications. For joint health, BPC-157 has more substantial preclinical and anecdotal evidence for tissue repair, though it also lacks large RCT validation. TB-500 (Thymosin Beta-4) is also used for joint/soft tissue recovery with similar evidence caveats. Evidence-based joint interventions include physical therapy, exercise, weight loss (for knee/hip osteoarthritis), and in some cases intra-articular hyaluronic acid or corticosteroid injections. AOD-9604 should not be considered an evidence-based joint or cartilage treatment.

    If I've been using AOD-9604 for months, should I continue or stop?

    Make an honest assessment: what measurable changes has AOD-9604 produced during your use? Compare against what you would expect from the concurrent lifestyle changes (caloric deficit, exercise, sleep) you've been making independently. If you cannot identify clear AOD-9604-specific benefits beyond what lifestyle factors would account for, consider discontinuing. Discontinuation has no withdrawal syndrome and no physiological concerns - simply stop. Redirect the resources (money, injection time, mental energy) to interventions with better evidence: nutrition planning, resistance training programming, sleep optimization, or evidence-based pharmacotherapy if clinically indicated. Many users find that when they stop AOD-9604, nothing meaningfully changes - which is consistent with the lack of efficacy evidence. This is information worth acting on rather than continuing out of inertia.

    What are the best evidence-based alternatives to AOD-9604 for fat loss?

    For pharmacologic fat loss with substantial clinical evidence, the options in order of typical efficacy are: (1) Tirzepatide (Zepbound/Mounjaro): GLP-1/GIP dual agonist, ~20-22% weight loss at 72 weeks in SURMOUNT-1; (2) Retatrutide: GLP-1/GIP/glucagon triple agonist, ~24% weight loss at 48 weeks in Phase 2 (Phase 3 ongoing); (3) Semaglutide (Wegovy/Ozempic): GLP-1 agonist, ~15-17% weight loss at 68 weeks in STEP-1; (4) oral Orforglipron with ~14-15% weight loss - an oral non-peptide GLP-1 approach; (5) Cagrilintide + GLP-1 (CagriSema): ~22.7% weight loss in Phase 3; (6) Tesamorelin: FDA-approved GHRH analog specifically effective for visceral fat reduction. Non-pharmacologic evidence-based interventions: structured resistance training (preserves/builds lean mass), caloric deficit with adequate protein (1.2-1.6 g/kg), sufficient sleep (7-9 hours), stress management (cortisol opposition). These interventions, alone or in combination, vastly outperform AOD-9604 based on clinical evidence.

    How many vendors sell AOD-9604, and what does it cost per mg?

    3 of the vendors BodyHackGuide tracks list AOD-9604 (5 listings). Among BodyHackGuide's AOD-9604 listings recorded as in stock with a milligram count, the lowest price per milligram is $7.00/mg at BioMyst Labs and the median is $7.00/mg. The AOD-9604 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a AOD-9604 listing is dated 8 October 2026.

    Which vendors have third-party COAs for AOD-9604 on file at BodyHackGuide?

    BodyHackGuide holds 73 third-party certificate records for AOD-9604, from Optimum Formula and Half Nattys. An editor has read 1 of BodyHackGuide's 73 certificate records for AOD-9604 and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's AOD-9604 certificate records are Vanguard Labs and Freedom Diagnostics Testing, and the newest test date on them is 2 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Related

    Articles on AOD-9604

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free